All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
During the European Society of Hematology (ESH) 2nd How I manage: CAR-T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to Ulrich Jӓger, Medical University of Vienna, Vienna, AT. We asked, What are the key updates from ESH 2nd How I manage: CAR-T therapies and bispecific antibodies?
What are the key updates from ESH: 2nd How I manage: CAR T therapies and bispecific antibodies?
Firstly, Jӓger discusses key topics, including the future of chimeric-antigen receptor T-cell therapy and bispecific antibody treatment, the toxicities involved in these treatments, the potential to combine both treatment options, and how to sequence treatments in specific indications. He also highlights key learnings across all indications from the meet-the-expert sessions and debates held at this congress.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox